Pharmaceuticals China

China Long-Acting HIV Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

China Long-Acting HIV Treatment Market Industry Trends and Forecast to 2034: Segmented by (Use, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $208.7 Mn Placeholder estimate
Estimate 2025 $254.0 Mn 8.8% of the global market
Projected 2034 $1.49 Bn 485.6% Adds $1.23 Bn over 9 forecast years
CAGR 2025–2034 21.7% Faster than 88% of 180 Pharmaceuticals markets here
Key players 4
  • China is 8.82% of the global market.
  • In APAC, the largest is China (this report) at $254.0 Mn.
  • Fastest growing: India at 22.6% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.23 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Long-Acting HIV Treatment Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $208.7 Mn — —
2025 (base) $254.0 Mn +$45.3 Mn —
2026 (forecast) $309.1 Mn +$55.1 Mn +21.7%
2027 (forecast) $376.2 Mn +$67.1 Mn +48.1%
2028 (forecast) $457.8 Mn +$81.6 Mn +80.2%
2029 (forecast) $557.2 Mn +$99.4 Mn +119.4%
2030 (forecast) $678.1 Mn +$120.9 Mn +167%
2031 (forecast) $825.3 Mn +$147.1 Mn +224.9%
2032 (forecast) $1.00 Bn +$179.1 Mn +295.4%
2033 (forecast) $1.22 Bn +$217.9 Mn +381.2%
2034 (forecast) $1.49 Bn +$265.2 Mn +485.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Long-Acting HIV Treatment Market Analysis at a glance
Market size, 2025$254.0 Mn placeholder estimate
Forecast, 2034$1.49 Bn placeholder estimate
Growth (CAGR), 2025–203421.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsUse, drug and end user (see all)
Key playersViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc. (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
Active clinical trials1 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Long-Acting HIV Treatment Market Analysis Executive Summary

Long-acting HIV treatments and prevention are given as injections every few months instead of daily pills.

Key segments of the long-Acting HIV Treatment market include use (Treatment and Pre-Exposure Prophylaxis (PrEP)) and drug (Cabotegravir, Lenacapavir and Rilpivirine).

Bar chart: China Long-Acting HIV Treatment market size, 2024–2034, placeholder estimates. $208.7 Mn in 2024, $254.0 Mn in 2025 and $1.49 Bn in 2034, 21.7% CAGR.
China Long-Acting HIV Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Long-Acting HIV Treatment Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the long-Acting HIV Treatment market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the long-Acting HIV Treatment market.

Competitive Landscape for Long-Acting HIV Treatment Market in China

The long-Acting HIV Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Long-Acting HIV Treatment Market in China

Long-Acting HIV Treatment in China: rules, payment and research

Drugs need approval from the National Medical Products Administration (NMPA) before sale.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] ClinicalTrials.gov lists 1 study on Long-Acting HIV Treatment that is recruiting, active or about to start in China.⁠[3]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for long-Acting HIV Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Long-Acting HIV Treatment right now, from free public sources.

Clinical trials

1 active trial in China

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. ViiV Healthcare 14 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Gilead Sciences, Inc. 6 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Long-Acting HIV Treatment in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Long-Acting HIV Treatment market in China?
Placeholder estimate: about $254.0 Mn in 2025, rising to about $1.49 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Long-Acting HIV Treatment market in China growing?
Placeholder estimate: about 21.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Long-Acting HIV Treatment market report cover?
The report splits the market by use (Treatment, Pre-Exposure Prophylaxis (PrEP)), drug (Cabotegravir, Lenacapavir, Rilpivirine) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Long-Acting HIV Treatment market?
Key players include ViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson and Merck & Co., Inc..
What is driving the Long-Acting HIV Treatment market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
Who regulates Long-Acting HIV Treatment in China?
Drugs need approval from the National Medical Products Administration (NMPA) before sale. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Long-Acting HIV Treatment are running in China?
1 study is recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
How much research is published on Long-Acting HIV Treatment?
PubMed lists 17 papers on Long-Acting HIV Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in China

See all

Related on hiv and infectious diseases

See the topic